Visual prosthetic device for bilateral end-stage macular degeneration

Expert Review of Medical Devices

Volumn 2, Issue 6, 2005, Pages 657-665

  Chun, Dal W ^a   Heier, Jeffrey S ^b   Raizman, Michael B ^b  

^a NEW ENGLAND EYE CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMD; Macular degeneration; Visual prosthesis

Indexed keywords

ALPHA TOCOPHEROL; ANECORTAVE; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; PEGAPTANIB; PHOTOSENSITIZING AGENT; RANIBIZUMAB; ZINC;

ARGON LASER; ARTICLE; BLINDNESS; CLINICAL TRIAL; DIODE LASER; DISEASE SEVERITY; DRUG MEGADOSE; DRUSEN; EQUIPMENT DESIGN; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; HUMAN; LASER COAGULATION; OUTPATIENT CARE; PERIPHERAL VISION; PHOTODYNAMIC THERAPY; QUALITY OF LIFE; RETINA IMAGE; RETINA MACULA AGE RELATED DEGENERATION; TRANSPUPILLARY THERMOTHERAPY; UNITED STATES; VISION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VISUAL PROSTHESIS;

EID: 28244465124     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2.6.657     Document Type: Article

References (23)

1. Gohdes DM, Balamurugan A, Larsen BA, Maylahn C. Age-related eye diseases: an emerging challenge for public health professionals. Prev. Chronic Dis. 2, A17 (2005).
2. Friedman DS, O'Colmain BJ, Munoz B et al., for the Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-572 (2004).
3. Age-Related Eye Disease Study Research Group. Potential public health impact of age-related eye disease study results. AREDS report no. 11. Arch. Ophthalmol. 121, 1621-1624 (2003).
4. Wang JJ, Mitchell P, Smith W, Cumming RG. Bilateral involvement by age related maculopathy lesions in a population. Br. J. Ophthalmol. 82, 743-747 (1998).
5. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III, Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report no. 19. Ophthalmology 112(4), 533-539 (2005).
6. Seddon JM, Rosner B, Sperduto RD et al. Dietary fat and risk for advanced age-related macular degeneration. Arch. Ophthalmol. 119(8), 1191-1199 (2001).
7. Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol. Vision 5, 25 (1999).
8. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch. Ophthalmol. 116, 514-520 (1998).
9. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr. Opin. Ophthalmol 15, 181-183 (2004).
10. Brown MM, Brown GC, Sharma S, Kistler J, Brwon H. Utility values associated with blindness in an adult population. Br. J. Ophthalmol. 85, 327-331 (2001).
11. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331(22), 1480-1487 (1994).
12. Ishida S, Usui T, Yamashiro K. VEGF164-mediated inflammation is required for pathological, but not physiological, ischaemia-induced retinal neovascularization. J. Exp. Med. 198(3), 483-489 (2003).
13. AREDS Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 119(10), 1439-1452 (2001).
14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin - TAP Report 2. Arch. Ophthalmol. 119, 198-207 (2001).
15. Gragoudas ES, Adamis AP, Cunningham ET et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816 (2004).
16. Adams E, Flynn K, Alligood E, Johnson T, Veterans Administration Technology Assessment Program. Optical devices for adults with low vision: a systematic review of published studies of effectiveness. Final report from the Office of Patient Care Services, May (2003).
17. Chow AY, Chow VY, Packo KR, Pollack JS, Peyman GA, Schuchard R. The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch. Ophthalmol. 122, 460-469 (2004).
18. Lane SS, Kuppermann BD, Fine IH et al. A prospective multicenter clinical trial to evaluate the safety and effectiveness of the Implantable Miniature Telescope. Am. J. Ophthalmol. 137, 993-1001 (2004).
19. The Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization-SST Report No. 1. Arch. Ophthalmol. 121, 531-539 (2003).
20. Mangione CM, Lee PP, Gutierrez PR. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch. Ophthalmol. 119, 1050-1058 (2001).
21. Mangione CM, Phillips RS, Seddon JM et al. Development of the 'Activities of Daily Vision Scale.' A measure of visual functional status. Med. Care 30, 1111-1126 (1992).
22. Globe DR, Wu J, Azen SP et al. The impact of visual impairment on self-reported visual functioning in Latinos. The Los Angeles Latino Eye Study. Ophthalmology 111(6), 1141-1149 (2004).
23. Fletcher DC, Schuchard RA. Preferred retinal loci relationship to macular scotomas in a low-vision population. Ophthalmology 104, 632-638 (1997).